The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Catherine A. Shu
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Genentech/Roche; Janssen; Mirati Therapeutics; Takeda
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Janssen (Inst)
 
Rachel E. Sanborn
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; G1 Therapeutics; Genentech/Roche; GlaxoSmithKline; Illumina; Janssen Oncology; Macrogenics; Mirati Therapeutics; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - AstraZeneca
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Calithera Biosciences; D2G Oncology; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria - AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding - AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Novocure
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Saiama Naheed Waqar
Research Funding - Abbvie (Inst); ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cullinan Pearl (Inst); Daiichi Sankyo (Inst); Elevation Oncology (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Ignyta (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Millennium (Inst); Newlink Genetics (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Roche (Inst); Verastem (Inst); Vertex (Inst); Xcovery (Inst)
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Janssen; Mirati Therapeutics; Mirati Therapeutics; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Pritam Kambuj
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Jeffrey Sanchez
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Lahila-Carina Ojeda
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
John Xie
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Parthiv Mahadevia
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Joshua Michael Bauml
Employment - Janssen Research & Development
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Foundation Medicine; Genentech; Guardant Health; Inivata; Janssen; Merck; Novartis; Novartis; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Roland E. Knoblauch
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Johnson & Johnson
 
Hidetoshi Hayashi
Honoraria - Amgen; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex